Amino-pyrrolopyrimidinone compounds and methods of use thereof

Abstract

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of BTK, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.

1 . A compound of Formula (I): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:
 A is (C 6 -C 10 ) aryl or 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally substituted with one or more R 4 ; 
 R 1  is (C 3 -C 7 ) cycloalkyl or 4- to 9-membered heterocyclyl comprising 1 to 3 heteroatoms selected from N, O, and S, wherein the cycloalkyl and heterocyclyl are optionally substituted with one or more R 5 ; 
 R 2  is H or (C 1 -C 4 ) alkyl; or 
 when q is 0, R 1  and R 2  together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclyl ring comprising 0 to 1 additional heteroatoms selected from N, O, and S and optionally substituted with one or more NR 6 R 7 ; 
 R 3  is H or N(R 5 ) 2 ; 
 each R 4  is independently (i) (C 1 -C 4 ) alkyl, (ii) (C 1 -C 4 ) alkoxy optionally substituted with one or more (C 1 -C 4 ) alkoxy, (iii) (C 1 -C 4 ) haloalkyl, (iv) (C 1 -C 4 ) haloalkoxy, (v) halogen, (vi) NR 9 S(O) p R 10 , (vii) O(CH 2 ) n R 11 , (viii) NH(CH 2 ) n R 11 1, (ix) (CH 2 ) n C(═O)NHR 25 , (x) (CH 2 ) n NHC(═O)R 25 , (xi) (CH 2 ) n NHC(═O)NHR 25 , (xii) C(═O)R 25 , or (xiii) heterocyclyl comprising one or two 4- to 6-membered rings and 1 to 3 heteroatoms selected from N, O, and S and optionally substituted with one or more substituents selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, C(═O)(C 1 -C 4 ) alkyl, and halogen; 
 each R 5  is independently (i) (C 1 -C 6 ) alkyl optionally substituted with one or more (C 1 -C 4 ) alkoxy or phenyl, (ii) (C 2 -C 4 ) alkenyl optionally substituted with one or more C(═O)(C 1 -C 4 ) alkyl, (iii) (C(R 12 ) 2 ) r OH, (iv) (C(R 12 ) 2 ) r NR 13 R 14 , (v) C(═O)OH, (vi) C(═O)O(C 1 -C 4 ) alkyl, (vii) C(═O)NR 13 R 15 , (viii) C(═O)R 16 , (ix) S(O) p R 16 , or (x) 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O, and S and optionally substituted with one or more (C 1 -C 4 ) alkyl, (xi) or two R 5  together with the carbon atom to which they are attached form (═O), or (xii) two R 5  together with the atoms to which they are attached form a bridged 3- to 6-membered heterocyclyl ring comprising 1 to 3 heteroatoms selected from N, O, and S; 
 R 6  is H or (C 1 -C 4 ) alkyl; 
 R 7  is H, (C 1 -C 4 ) alkyl, or C(═O)R 24 ; 
 each R 8  is independently (i) H, (ii) (C 1 -C 4 ) alkyl, or (iii) 5- or 6-membered heterocyclyl comprising 1 to 3 heteroatoms selected from N, O, and S and optionally substituted with one or more (C 1 -C 4 ) alkyl, or (iv) two R 8  together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclyl ring comprising 0 to 1 additional heteroatoms selected from N, O, and S and optionally substituted with one or more (C 1 -C 4 ) alkyl; 
 R 9  is H or (C 1 -C 4 ) alkyl; 
 R 10  is (C 1 -C 4 ) alkyl or (C 6 -C 10 ) aryl; 
 R 11  is (C 3 -C 7 ) cycloalkyl, (C 4 -C 7 ) cycloalkenyl, (C 6 -C 10 ) aryl, or 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally substituted with one or more R 17 ; 
 each R 12  is independently H or (C 1 -C 6 ) alkyl; 
 R 13  is H or (C 1 -C 4 ) alkyl; 
 R 14  is (i) H, (ii) (C 1 -C 4 ) alkyl, (iii) (C(R 18 ) 2 ) r C(═O)NR 19 R 20 , (iv) (CH 2 ) n (C 6 -C 10 ) aryl optionally substituted with one or more (C 1 -C 4 ) alkyl or halogen, (v) C(═O)R 21 , (vi) C(═O)O(C 1 -C 4 ) alkyl, (vii) S(O) 2 (C 1 -C 8 ) alkyl, (viii) S(O) 2 NH(C 1 -C 8 ) alkyl, (ix) S(O) 2 N((C 1 -C 8 ) alkyl) 2 , or (x) C(═O)(C 1 -C 8 ) alkyl optionally substituted with one or more R 22 ; or 
 R 13  and R 14  together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocyclyl ring comprising 1 to 3 heteroatoms selected from N, O, and S and optionally substituted with one or more substituents selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, OH, NH 2 , and (═O); 
 R 15  is (i) H, (ii) 5- or 6-membered heterocyclyl comprising 1 to 3 heteroatoms selected from N, O, and S, or (iii) (C 1 -C 4 ) alkyl optionally substituted with one or more substituents selected from OH, 5- or 6-membered heterocyclyl comprising 1 to 3 heteroatoms selected from N, O, and S, and 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O, and S; or 
 R 13  and R 15  together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocyclyl ring comprising 1 to 3 heteroatoms selected from N, O, and S and optionally substituted with one or more substituents selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, and OH, or form a 5- to 8-membered bicyclic heterocyclyl ring comprising 1 to 3 heteroatoms selected from N, O, and S and optionally substituted with one or more substituents selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, and OH; 
 R 16  is (C 1 -C 4 ) alkyl, (C 2 -C 4 ) alkenyl, (C 2 -C 4 ) alkynyl, or 3- to 6-membered heterocyclyl comprising 1 to 3 heteroatoms selected from N, O, and S, wherein the alkyl, alkenyl, and alkynyl are optionally substituted with one or more substituents selected from (C 1 -C 4 ) alkoxy, O-phenyl, halogen, CN, NH 2 , (C 1 -C 4 ) alkylamino, di-(C 1 -C 4 ) alkylamino, and OS(O) 2 (C 1 -C 4 ) alkyl, and wherein the heterocyclyl is optionally substituted with one or more R 23 ; 
 each R 17  is independently (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, C(═O)NH 2 , C(═O)NH(C 1 -C 4 ) alkyl, or C(═O)N((C 1 -C 4 ) alkyl) 2 ; 
 each R 18  is independently H or (C 1 -C 4 ) alkyl; 
 R 19  is H or (C 1 -C 4 ) alkyl; 
 R 20  is H or (CH 2 ) n (C 6 -C 10 ) aryl optionally substituted with one or more (C 1 -C 4 ) alkyl; 
 R 21  is (C 3 -C 7 ) cycloalkyl, 5- or 6-membered heterocyclyl comprising 1 to 3 heteroatoms selected from N, O, and S, (C 6 -C 10 ) aryl, or 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl, heteroaryl, cycloalkyl, and heterocyclyl are optionally substituted with one or more substituents selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, OH, and halogen; 
 each R 22  is independently (i) (C 1 -C 4 ) alkoxy, (ii) OH, (iii) NH 2 , (iv) (C 1 -C 4 ) alkylamino, (v) di-(C 1 -C 4 ) alkylamino, or (vi) 5- or 6-membered heterocyclyl comprising 1 to 3 heteroatoms selected from N, O, and S and optionally substituted with one or more substituents selected from (a) (C 1 -C 4 ) alkyl, (b) (CH 2 ) x (C 6 -C 10 ) aryl, and (c) C(═O)(C 6 -C 10 )aryl optionally substituted with one or more (C 1 -C 4 ) alkyl; 
 each R 23  is independently (C 1 -C 4 ) alkyl or C(═O)(C 1 -C 4 ) alkyl, or two R 23  together with the atoms to which they are attached form a 5- or 6-membered heterocyclyl ring comprising 1 to 3 heteroatoms selected from N, O, and S; 
 R 24  is (C 1 -C 4 ) alkyl optionally substituted with one or more substituents selected from (C 1 -C 4 ) alkoxy and 5- or 6-membered heterocyclyl comprising 1 to 3 heteroatoms selected from N, O, and S; 
 R 25  is (C 1 -C 4 ) alkyl optionally substituted with one or more (C 1 -C 4 ) alkoxy, (C(R 26 ) 2 ) x (C 6 -C 10 ) aryl, (C(R 26 ) 2 ) x -heteroaryl, wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1 to 3 heteroatoms selected from N, O, and S, or (C(R 26 ) 2 ) x -heterocyclyl, wherein the heterocyclyl comprises one or two 4- to 6-membered rings and 1 to 3 heteroatoms selected from N, O, and S, wherein the alkyl, alkoxy, aryl, heteroaryl, and heterocyclyl are optionally substituted with one or more substituents selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, cyano, halogen, OH, NH 2 , (C 6 -C 10 ) aryl, and 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O, and S; 
 each R 26  is independently H or (C 1 -C 4 ) alkyl, or two R 26  together with the atom to which they are attached form a (C 3 -C 6 ) cycloalkyl ring or 3- or 6-membered heterocyclyl ring comprising 1 to 3 heteroatoms selected from N, O, and S; 
 each n and each p is independently 0, 1, or 2; 
 each r is independently 0, 1, 2, or 3; 
 each q and each x is independently 0, 1, 2, or 3; and 
 provided that when R 4  is NR 9 S(O) p R 10 , A is optionally substituted with one additional R 4 ; and 
 provided that the compound is not (2-chloro-4-phenoxyphenyl)(4-(((3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)methanone. 
 
     
     
         2 . The compound of  claim 1 , wherein A is phenyl, thiophenyl, or pyridinyl optionally substituted with one or more R 4 . 
     
     
         3 . The compound of  claim 1 , wherein A is phenyl, thiophenyl, or pyridinyl substituted with one to two R 4 . 
     
     
         4 . The compound of  claim 1 , wherein A is phenyl substituted with one to two R 4 . 
     
     
         5 . The compound of  claim 1 , wherein R 2  is H. 
     
     
         6 . The compound of  claim 1 , wherein R 3  is H, NH 2 , NHCH 3 , or 4-methylpiperazine. 
     
     
         7 . The compound of  claim 1 , wherein R 3  is H. 
     
     
         8 . The compound of  claim 1 , wherein each R 4  is independently (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy optionally substituted with one or more (C 1 -C 4 ) alkoxy, halogen, NR 9 S(O) p R 10 , O(CH 2 ) n R 11 , NH(CH 2 ) n R 11 , (CH 2 ) n C(═O)NHR 25 , (CH 2 ) n NHC(═O)R 25 , (CH 2 ) n NHC(═O)NHR 25 , C(═O)R 25 , or heterocyclyl comprising one or two 4- to 6-membered rings and 1 to 3 heteroatoms selected from N, O, and S and optionally substituted with one or more substituents selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, C(═O)(C 1 -C 4 ) alkyl, and halogen. 
     
     
         9 . The compound of  claim 1 , wherein each R 4  is independently (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy optionally substituted with one or more (C 1 -C 4 ) alkoxy, halogen, (CH 2 ) n C(═O)NHR 25 , (CH 2 ) n NHC(═O)R 25 , (CH 2 ) n NHC(═O)NHR 25 , or C(═O)R 25 . 
     
     
         10 . The compound of  claim 1 , wherein at least one R 4  is C(═O)NHR 25 , NHC(═O)R 25 , (CH 2 )C(═O)NHR 25 , or (CH 2 )NHC(═O)R 25 . 
     
     
         11 . The compound of  claim 1 , wherein at least one R 4  is (CH 2 )NHC(═O)R 25 . 
     
     
         12 . The compound of  claim 1 , wherein at least one R 4  is heterocyclyl comprising one or two 4- to 6-membered rings and 1 to 3 heteroatoms selected from N, O, and S and optionally substituted with one or more substituents selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, C(═O)(C 1 -C 4 ) alkyl, and halogen. 
     
     
         13 . The compound of  claim 1 , wherein R 11  is (C 6 -C 10 ) aryl or 5- or 6-membered heteroaryl comprising 1 to 3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are optionally substituted with one to three R 17 . 
     
     
         14 . The compound of  claim 1 , wherein R 11  is phenyl or pyridinyl, and is optionally substituted with one to three R 17 . 
     
     
         15 . The compound of  claim 1 , wherein R 1  is (C 4 -C 7 ) cycloalkyl substituted with one to three R 5 . 
     
     
         16 . The compound of  claim 1 , wherein R 1  is cyclohexyl substituted with one to three R 5 . 
     
     
         17 . The compound of  claim 1 , wherein R 1  is 4- to 7-membered heterocyclyl comprising 1 to 3 heteroatoms selected from N, O, and S optionally substituted with one to three R 5 . 
     
     
         18 . The compound of  claim 1 , wherein R 1  is piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, or 1,4-dioxanyl optionally substituted with one to three R 5 . 
     
     
         19 . The compound of  claim 1 , wherein R 1  is tetrahydropyranyl optionally substituted with one to three R 5 . 
     
     
         20 . The compound of  claim 1 , wherein R 5  is C(═O)R 16  or S(O) p R 16  and R 16  is (C 2 -C 4 ) alkenyl or (C 2 -C 4 ) alkynyl, wherein the alkenyl and alkynyl are optionally substituted with one or more CN. 
     
     
         21 . The compound of  claim 1 , wherein two R 5  together with the atoms to which they are attached form a bridged 3- to 6-membered heterocyclyl ring comprising 1 to 3 heteroatoms selected from N, O, and S. 
     
     
         22 . The compound of  claim 1 , wherein q is 0 or 1. 
     
     
         23 . The compound of  claim 1 , wherein the compound is of Formula (Ia′), (Ib′), or (Ic′): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, or tautomer thereof, wherein w is 1 or 2. 
     
     
         24 . The compound of  claim 1 , wherein the compound is of Formula (Id′), (Ie′), or (If′): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R 5 ′ is H or R 5 . 
     
     
         25 . The compound of  claim 1 , wherein the compound is of any of Formulae (Ig1)-(Ig12), (Ih1)-(Ih12), and (Ii1)-(Ii12): 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, or tautomer thereof. 
     
     
         26 . A pharmaceutical composition comprising a compound of  claim 1 , or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable diluent, excipient or carrier. 
     
     
         27 . A method of treating a BTK-mediated disorder, comprising administering to a subject in need thereof a compound of  claim 1 , or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer, or tautomer thereof.